• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Christopher Simon to the Board of Directors

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $HAE alert in real time by email

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.

    For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previously, Mr. Simon served as a Senior Partner of McKinsey & Company, a strategy and management consulting firm, where he led the Global Medical Products Practice. Prior to his career at McKinsey & Company, Mr. Simon served in commercial and operating roles at Baxter Healthcare Corporation, now Baxter International Inc., a healthcare company, and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion. He brings more than 30 years of experience in helping businesses transform and grow.



    "We are excited to welcome Chris to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Chris's leadership experience as a public company CEO and his extensive commercial and strategic experience in the life sciences industry will serve as tremendous assets as we continue to grow."

    Mr. Simon also currently serves on the board of directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts 
    Jason Peterson

    Vice President Investor Relations & Treasurer, Sotera Health

    [email protected]
     
      
      
    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    [email protected]
     

    Source: Sotera Health Company



    Primary Logo

    Get the next $HAE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAE
    $SHC

    CompanyDatePrice TargetRatingAnalyst
    Haemonetics Corporation
    $HAE
    8/11/2025$78.00Strong Buy → Outperform
    Raymond James
    Haemonetics Corporation
    $HAE
    8/8/2025$62.00Overweight → Neutral
    Analyst
    Haemonetics Corporation
    $HAE
    8/8/2025$95.00 → $86.00Outperform
    Barrington Research
    Haemonetics Corporation
    $HAE
    7/9/2025$90.00Neutral → Buy
    Citigroup
    Haemonetics Corporation
    $HAE
    6/26/2025$87.00Outperform
    Robert W. Baird
    Sotera Health Company
    $SHC
    5/5/2025$17.00Neutral → Buy
    Goldman
    Haemonetics Corporation
    $HAE
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    Sotera Health Company
    $SHC
    12/6/2024$14.00Neutral
    Goldman
    More analyst ratings

    $HAE
    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Sotera Health Announces Second-Quarter 2025 Earnings Release Date

    CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A live

    7/28/25 7:38:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 11,508 shares, decreasing direct ownership by 6% to 189,602 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    8/7/25 6:09:02 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Director Zane Ellen M was granted 2,693 shares, increasing direct ownership by 16% to 19,373 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:36:13 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Pomeroy Claire was granted 2,693 shares, increasing direct ownership by 19% to 16,872 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:33:39 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haemonetics downgraded by Raymond James with a new price target

    Raymond James downgraded Haemonetics from Strong Buy to Outperform and set a new price target of $78.00

    8/11/25 9:46:26 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics downgraded by Analyst with a new price target

    Analyst downgraded Haemonetics from Overweight to Neutral and set a new price target of $62.00

    8/8/25 8:19:52 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Haemonetics with a new price target

    Barrington Research reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $86.00 from $95.00 previously

    8/8/25 7:34:13 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    SEC Filings

    View All

    SEC Form 10-Q filed by Sotera Health Company

    10-Q - Sotera Health Co (0001822479) (Filer)

    8/8/25 4:19:13 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sotera Health Co (0001822479) (Filer)

    8/8/25 7:44:28 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by Haemonetics Corporation

    10-Q - HAEMONETICS CORP (0000313143) (Filer)

    8/7/25 6:08:06 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Sotera Health Announces Second-Quarter 2025 Earnings Release Date

    CLEVELAND, July 28, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the second-quarter ended June 30, 2025 before the market opens on Friday, August 8, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A live

    7/28/25 7:38:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $HAE
    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by Haemonetics Corporation

    SC 13G - HAEMONETICS CORP (0000313143) (Subject)

    11/14/24 1:28:29 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services